



US009409868B2

(12) **United States Patent**
Schonbrunn et al.

(10) **Patent No.:** **US 9,409,868 B2**
(45) **Date of Patent:** **Aug. 9, 2016**

(54) **INHIBITORS OF RHO ASSOCIATED
PROTEIN KINASES (ROCK) AND METHODS
OF USE**

2002/0120100 A1 8/2002 Bonny
2002/0173507 A1 11/2002 Santora et al.
2003/0032594 A1 2/2003 Bonny

(71) Applicant: **H. LEE MOFFITT CANCER
CENTER AND RESEARCH
INSTITUTE, INC.**, Tampa, FL (US)

FOREIGN PATENT DOCUMENTS

WO 2004064730 A2 8/2004
WO 2010036316 A1 4/2010

(72) Inventors: **Ernst Schonbrunn**, Tampa, FL (US);
Rongshi Li, Omaha, NE (US); **Said M.
Sebti**, Tampa, FL (US)

OTHER PUBLICATIONS

(73) Assignee: **H. Lee Moffitt Cancer Center and
Research Institute, Inc.**, Tampa, FL
(US)

Database Registry Chemical Abstracts Service, Columbus, Ohio,
Accession No. RN 1055941-86-0, Entered STN: Oct. 1, 2008.*

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

Shimokawa, et al., Development of Rho-kinase inhibitors for cardio-
vascular medicine, Trends Pharmacol Sci, 28:296-302, 2007.

(21) Appl. No.: **14/374,445**

Somlyo, et al., Rho-Kinase Inhibitor Retards Migration and in Vivo
Dissemination of Human Prostate Cancer Cells, Biochem Biophys
Res Commun, 269:652-659, 2000.

(22) PCT Filed: **Jan. 24, 2013**

Somlyo, et al., Rho kinase and matrix metalloproteinase inhibitors
cooperate to inhibit angiogenesis and growth of human prostate
cancer xenotransplants, Faseb J, 17:223-234, 2003.

(86) PCT No.: **PCT/US2013/022965**

§ 371 (c)(1),
(2) Date: **Jul. 24, 2014**

Suwa, et al., Overexpression of the rhoC gene correlates with pro-
gression of ductal adenocarcinoma of the pancreas, Br J Cancer,
77:147-152, 1998.

(87) PCT Pub. No.: **WO2013/112722**

PCT Pub. Date: **Aug. 1, 2013**

Takami, et al., Design and synthesis of Rho kinase inhibitors (I),
Bioorg Ivfed Chem, 12:2115-2137, 2004.

(65) **Prior Publication Data**

US 2014/0336440 A1 Nov. 13, 2014

Thomas, et al., The Pilot Phase of the NIH Chemical Genomics
Center, Curr. Top. Med. Chem., 9:1184-1193, 2009.

Related U.S. Application Data

Toyoizumi, et al., Combined therapy with chemotherapeutic agents
and herpes simplex virus type IICP34.5 mutant (HSV-1716) in
human non-small cell lung cancer, Human Gene Therapy, 10(18)17,
1999.

(60) Provisional application No. 61/590,283, filed on Jan.
24, 2012, provisional application No. 61/590,573,
filed on Jan. 25, 2012.

Uchida, et al., The Suppression of Small GTPase Rho Signal
Transduction Pathway Inhibits Angiogenesis in Vitro and in Vivo,
Biochem Biophys Res Commun, 269:633-640, 2000.

(51) **Int. Cl.**

C07D 231/56 (2006.01)
C07D 213/40 (2006.01)
C07D 213/36 (2006.01)
A61K 45/06 (2006.01)
A61K 31/416 (2006.01)
A61K 31/4418 (2006.01)
A61N 5/10 (2006.01)

Uehata, et al., Calciumsensitization of smooth musclemediated by a
Rho-associated protein kinase in hypertension, Nature, 389:990-4,
1997.

(52) **U.S. Cl.**

CPC **C07D 231/56** (2013.01); **A61K 31/416**
(2013.01); **A61K 31/4418** (2013.01); **A61K**
45/06 (2013.01); **A61N 5/10** (2013.01); **C07D**
213/36 (2013.01); **C07D 213/40** (2013.01)

Xing, et al., Rho-kinase as a Potential Therapeutic Target for the
Treatment of Pulmonary Hypertension, Drug News Perspect,
19:517-522, 2006.

Yin, et al., Discovery of Potent and Selective Urea-Based ROCK
Inhibitors and Their Effects on Intraocular Pressure in Rats, Med.
Chem. Lett., 1:175-179, 2010.

Yin, et al., Benzothiazoles as Rho-associated kinase (ROCK-II)
inhibitors, Bioorg. Med. Chem. Lett., 19:6686-6690, 2009.

Ying, et al., The Rho kinase inhibitor fasudil inhibits tumor progres-
sion in human and rat tumor models, Mal Cancer Ther, 5:2158-2164,
2006.

(Continued)

(58) **Field of Classification Search**

None
See application file for complete search history.

Primary Examiner — Samantha Shterengarts

(74) *Attorney, Agent, or Firm* — Meunier Carlin & Curfman
LLC

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,960,648 B2 11/2005 Bonny
2002/0035243 A1 3/2002 Imfeld et al.

(57) **ABSTRACT**

Compounds and compositions having activity as inhibitors of
Rho-associated protein kinases (ROCKs), and methods of
making and using the subject compounds are disclosed.

5 Claims, 6 Drawing Sheets